Skip to Main Content

Our people-our expertise: Dr Timothy Kidd

Our people-our expertise

Dr Timothy Kidd

Qualifications | Research interests | Publications | Presentations | Awards | Grants and funding | Memberships / Affiliations

Tim completed his initial undergraduate studies at QUT in 1992, and thereafter worked as a scientist within various clinical microbiology laboratories (including Pathology Queensland) located throughout Brisbane. In 2007 he commenced full-time research, receiving his PhD at UQ in 2012. In 2014 he was awarded a Marie Skłodowska-Curie Research Fellowship based at Queen’s University Belfast; thereafter relocating to the UQ School of Chemistry and Molecular Biosciences in 2017 supported by an NHMRC ECF. In 2020, Tim returned to the Pathology Queensland Central Microbiology laboratory where he currently holds a Senior Scientist position specialising in the development, validation and implementation of molecular diagnostic assays including next generation sequencing.

ORCID: https://orcid.org/0000-0002-6135-6364

Google Scholar: https://scholar.google.com/citations?hl=en&user=Z7WSUUwAAAAJ

Qualifications

  • PhD in Medical Microbiology: 'Diagnosis, epidemiology and population structure of Pseudomonas aeruginosa in cystic fibrosis', The University of Queensland.

  • Bachelor of Applied Science (Microbiology/Biotechnology), Queensland University of Technology, Brisbane, Queensland.

  • Associate Diploma in Clinical Techniques, Queensland University of Technology, Brisbane, Queensland.

Research interests and expertise

  • Expanding understanding of acquisition, epidemiology, antimicrobial resistance and pathogenesis of acute and chronic Gram-negative bacterial infections.
  • Next generation sequencing and its application to clinical pathology.

Publications

2022

Nguyen TT, He C, Carter R, Ballard EL, Smith K, Groth R, Jaatinen E, Kidd TJ, Thomson RM, Tay G, Johnson GR, Bell SC, Knibbs LD, (2022). Quantifying the effectiveness of ultraviolent-C light at inactivating airborne Mycobacterium abscessus. J Hosp Infect. doi: 10.1016/j.jhin.2022.10.008

Nguyen TT, He C, Carter R, Ballard EL, Smith K, Groth R, Jaatinen E, Kidd TJ, Nguyen TK, Stockwell RE, Tay G, Johnson GR, Bell SC, Knibbs LD, (2022). The Effectiveness of Ultraviolet-C (UV-C) Irradiation on the Viability of Airborne Pseudomonas aeruginosa. Int J Envrion Res Public Health. doi: 10.3390/ijerph192013706

Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart AG, Subedi S, Choong K, Fraser TA, Sarovich DS, Price EP, (2022). Rapid fluroquinolone resistance detection in Pseudomonas aeruginosa using mismatch amplification mutation assay-bases real-time PCR. J Med Microbiol. doi: 10.1099/jmm.0.001593

Isler B, Paterson DL, Harris PNA, Ling W, Edwards F, Rickard CM, Kidd TJ, Gassiep I, Laupland KB. (2022). Achromobacter Species: An Emerging Cause of Community-Onset Bloodstream Infections. Microorganisms, 10 (7) 1449, 1449. doi: 10.3390/microorganisms10071449

Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood K, Sidjabat HE, Whiley DM, Beatson SA, Kidd TJ, Bell SC. (2022) Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. J Cyst Fibros; 21(1) : e35-e43. doi: 10.1016/j.jcf.2021.03.007.

2021

Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE , Grimwood K, Sidjabat HE, Whiley DM, Beatson SA, Kidd TJ, Bell SC. (2021). Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. Journal of Cystic Fibrosis, 21 (1), e35-e43. doi: 10.1016/j.jcf.2021.03.007

Chacko A, Sly PD, Kidd T, Gauld L (2021). Persistent Pseudomonas aeruginosa infection associated with non-invasive ventilation in a child with spinal muscular atrophy type 1. Journal of Clinical Sleep Medicine, 17 (3), 595-599. doi: 10.5664/jcsm.9014

2020

De Oliveira DMP, Bohlmann L, Conroy T, Jen FE, Everest-Dass A, Hansford KA, Bolisetti R, El-Deeb IM, Forde BM, Phan MD, Lacey JA, Tan A, Rivera-Hernandez T, Brouwer S, Keller N, Kidd TJ, Cork AJ, Bauer MJ, Cook GM, Davies MR, Beatson SA, Paterson DL, McEwan AG, Li J, Schembri MA, Blaskovich MAT, Jennings MP, McDevitt CA, von Itzstein M, Walker MJ. (2020). Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis. Sci Transl Med ;12(570): eabb3791. doi: 10.1126/scitranslmed.abb3791.

Ambroa A, Blasco L, López-Causapé C, Trastoy R, Fernandez-García L, Bleriot I, Ponce-Alonso M, Pacios O, López M, Cantón R, Kidd TJ, Bou G, Oliver A, Tomás M. (2020) Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274). Front Microbiol; 11:556706. doi: 10.3389/fmicb.2020.556706. eCollection 2020.

Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. (2020) Achromobacter Infections and Treatment Options. Antimicrob Agents Chemother 2020; 64(11):e01025-20. doi: 10.1128/AAC.01025-20.

Price EP, Soler Arango V, Kidd TJ, Fraser TA, Nguyen TK, Bell SC, Sarovich DS. (2020) Duplex real-time PCR assay for the simultaneous detection of Achromobacter xylosoxidans and Achromobacter spp. Microb Genom; 6(7):mgen000406. doi: 10.1099/mgen.0.000406.

De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ. (2020) Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev; 33(3):e00181-19. doi: 10.1128/CMR.00181-19.

Pearson T, Sahl JW, Hepp CM, Handady K, Hornstra H, Vazquez AJ, Settles E, Mayo M, Kaestli M, Williamson CHD, Price EP, Sarovich DS, Cook JM, Wolken SR, Bowen RA, Tuanyok A, Foster JT, Drees KP, Kidd TJ, Bell SC, Currie BJ, Keim P. (2020) Pathogen to commensal? Longitudinal within-host population dynamics, evolution, and adaptation during a chronic >16-year Burkholderia pseudomallei infection. PLoS Pathog; 16(3):e1008298. doi: 10.1371/journal.ppat.1008298.

2019

Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen TK, Kidd TJ, Nimmo GR, Sarovich DS, Price EP. (2019) Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen Stenotrophomonas maltophilia. Microb Genom Oct;5(10):e000307. doi: 10.1099/mgen.0.000307.

Nhu NTK, Phan MD, Forde BM, Murthy AMV, Peters KM, Day CJ, Poole J, Kidd TJ, Welch RA, Jennings MP, Ulett GC, Sweet MJ, Beatson SA, Schembri MA. (2019) Complex Multilevel Control of Hemolysin Production by Uropathogenic Escherichia coli. mBio; 10(5):e02248-19. doi: 10.1128/mBio.02248-19.

Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P. (2019) Antimicrobial Resistance International Working Group in Cystic Fibrosis. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis.Oct 30;69(10):1812-1816. doi: 10.1093/cid/ciz364.

Stockwell RE, Chin M, Johnson GR, Wood ME, Sherrard LJ, Ballard E, O'Rourke P, Ramsay KA, Kidd TJ, Jabbour N, Thomson RM, Knibbs LD, Morawska L, Bell SC. (2019) Transmission of bacteria in bronchiectasis and chronic obstructive pulmonary disease: Low burden of cough aerosols. Respirology; 24(10):980-987. doi: 10.1111/resp.13544.

Batholomew TL, Kidd TJ, Sá Pessoa J, Conde-Álvarez R, Bengoechea JA. (2019) 2-hydroxylation of Acinetobacter baumannii lipid A contributes to virulence. Infect Immun; 87(4):e00066-19. doi: 10.1128/IAI.00066-19

Kidd TJ, Grimwood K, Bell SC. (2019) Abolition of Pseudomonas aeruginosa AUST-01 from an Australian CF center: Do other strains remain? Pediatr Pulmonol; 54(5):515-516. doi: 10.1002/ppul.24258.

2018

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ. (2018) Antimicrobial Resistance in Cystic Fibrosis International Working Group. Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros; 17(6):696-704. doi: 10.1016/j.jcf.2018.08.014.

Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid DW, Brockway B, Lamont IL. (2018) Expression of Pseudomonas aeruginosa antibiotic resistance genes varies greatly during infections in cystic fibrosis patients. Antimicrob Agents Chemother; 62(11): pii: e01789-18. doi: 10.1128/AAC.01789-18

Stockwell RE, Wood ME, He C, Sherrard LJ, Ballard EL, Kidd TJ, Johnson GR, Knibbs LD, Morawska L, Bell SC, CF Cough Aerosol Group. (2018) Face masks reduce the release of Pseudomonas aeruginosa cough aerosols when worn for clinically relevant periods. Am J Resp Crit Care Med ; 198(10): 1339-1342. doi: 10.1164/rccm.201805-0823LE

Zowawi HM, Syrmis MW, Kidd TJ, Balkhy HH, Walsh TR, Al Johani SM, Al Jindan RY, Alfaresi M, Ibrahim E, Al-Jardani A, Al Salman J, Dashti AA, Sidjabat HE, Baz O, Trembizki E, Whiley DM, Paterson DL. (2018) Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region. J Med Microbiol; 67(6): 846-853. doi: 10.1099/jmm.0.000730

McCarthy KL, Wailan AM, Jennison AV, Kidd TJ, Paterson DL. (2018) Pseudomonas aeruginosa blood stream infection isolates: A "full house" of virulence genes in isolates associated with rapid patient death and patient survival. Microb Pathog;11(9): 81-85. doi: 10.1016/j.micpath.2018.03.062

Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. (2018) Transcriptomic analysis of longitudinal Burkholderia pseudomallei infecting the cystic fibrosis lung. Microb Genom; 4(8): Epub 2018. doi: 10.1099/mgen.0.000194

Wee BA, Tai AS, Sherrard LJ, Ben Zakour NL, Hanks KR, Kidd TJ, Ramsay KA, Lamont I, Whiley DM, Bell SC, Beatson SA. (2018) Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre. BMC Genomics; 19(1): 644. doi: 10.1186/s12864-018-5018-x

Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Kidd TJ, Cheney J, Ballard E, O'Rourke P, Jabbour N, Wainwright CE, Knibbs LD, Sly PD, Morawska L and Bell SC. (2018) Cystic fibrosis pathogens survive for extended periods within cough generated droplet nuclei. Thorax; 74(1): 87-90. doi: 10.1136/thoraxjnl-2018-211567

2017

Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Jabbour N, Ballard E, O'Rourke P, Kidd TJ, Wainwright CE, Knibbs LD, Sly PD, Morawska L, Bell SC. (2017) Face masks and cough etiquette reduce the cough aerosol concentration of Pseudomonas aeruginosa in people with CF. Am J Resp Crit Care Med; 197(3): 338-55. doi: 10.1164/rccm.201707-1457OC

Tai AS, Sherrard LJ, Kidd TJ, Ramsay KA, Buckley C, Syrmis M, Grimwood K, Bell SC, Whiley DM. (2017) Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis. BMC Pulm Med; 17(1): 138. doi: 10.1186/s12890-017-0482-7

Mills G, Dumigan A, Kidd TJ, Hobley L, Bengoechea JA. (2017) Identification and characterization of two Klebsiella pneumoniae lpxL lipid A late acyltransferases and their role in virulence. Infect Immun; 85(9).pii: e00068-17. doi: 10.1128/IAI.00068-17

He C, Mackay IM, Ramsay K, Liang Z, Kidd T, Knibbs LD, Johnson G, McNeale D, Stockwell R, Coulthard MG, Long DA, Williams TJ, Duchaine C, Smith N, Wainwright C, Morawska L. (2017) Particle and bioaerosol characteristics in a paediatric intensive care unit. Environ Int; 107:89-99. doi: 10.1016/j.envint.2017.06.020

McCarthy KL, Kidd TJ, Paterson DL. (2017) Pseudomonas aeruginosa blood stream infection isolates from patients with recurrent blood stream infection: Is it the same genotype? Epidemiol Infect; 145(14):3040-3046. doi: 10.1017/S0950268817001832

López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, Figuerola J, Cantón R, Kidd TJ, Molin S, Oliver A. (2017)  Evolution of the Pseudomonas aeruginosa mutational resistome in an international CF clone. Sci Rep; 7(1):5555. doi: 10.1038/s41598-017-05621-5

Sherrard LJ, Tay GT, Butler CA, Wood ME, Yerkovich S, Ramsay KA, Reid DW, Moore VL, Kidd TJ, Bell SC. (2017) Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in CF. Eur Respir J 2017; 49(5). pii: 1700046. doi: 10.1183/13993003.00046-2017

Viberg LT, Sarovich DS, Kidd TJ, Geake JB, Bell SC, Currie BJ, Price EP. (2017) Within-host evolution of Burkholderia pseudomallei during chronic infection of seven Australasian CF patients. MBio; 8(2). pii: e00356-17. doi: 10.1128/mBio.00356-17

Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA, Bell SC. (2017) Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis. PLoS One; 12(3):e0172179. doi: 10.1371/journal.pone.0172179

Kidd TJ, Mills G, Sá-Pessoa J, Dumigan A, Frank CG, Insua JL, Ingram R, Hobley L, Bengoechea JA. (2017) A Klebsiella pneumoniae antibiotic resistance mechanism that subdues host defences and promotes virulence. EMBO Molec Med; 9(4):430-447. doi: 10.15252/emmm.201607336

Presentations

Aug 2019: Invited speaker Understanding Antimicrobial Resistance in People With CF, 13th Australasian Cystic Fibrosis Conference, Perth, Western Australia.

Aug 2019: Session Chair, Infection, Microbiology & Immunology Oral Presentation & E-poster Sessions, 13th Australasian Cystic Fibrosis Conference, Perth, Western Australia.

Aug 2019: Session Chair, Challenging Infections Workshop, 13th Australasian Cystic Fibrosis Conference, Perth, Western Australia.

Apr 2019: Speaker selected from abstract, Global gene expression profiling of a virulent Klebsiella pneumoniae strain during pulmonary infection, Microbiology Society Annual Conference, Belfast, UK.

July 2018: Invited speaker, Epidemiology, mechanisms and implications of colistin resistance in Klebsiella pneumoniae, 2018 Australian Society for Microbiology Annual Scientific Meeting, Brisbane, Queensland.

June 2018: Invited speaker, Infection control and transmissibility in cystic fibrosis – what is clear and what is not?, 41st European Cystic Fibrosis Conference, Belgrade, Serbia.

Nov 2018: Invited speaker, What do we mean by antimicrobial resistance?, Antimicrobial Resistance Symposium North American Cystic Fibrosis Conference, Philadelphia, USA.

Sept 2017: Speaker selected from abstract, Colistin resistance in Klebsiella pneumoniae promotes virulence and attenuates host defence responses, BacPath 14, Adelaide Hills, South Australia.

Apr 2017: Invited Symposium speaker, The cystic fibrosis patient in the diagnostic microbiology laboratory, 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria.

Awards

  • 2018 Australian Infectious Diseases Research Centre Eureka Prize
  • 2017 Oral Presentation Award, BacPath '14 Meeting
  • 2013 The University of Queensland Dean's Award for Research Higher Degree Excellence

Grants and funding

  • Dynamics and clinical implications of outer membrane remodelling among multidrug resistant Klebsiella pneumoniae and Pseudomonas aeruginosa CI, Australian Infectious Diseases Research Centre Research Excellence Award 2018-2019, $50,000
  • Epidemiology, virulence and antibiotic resistance of pyogenic liver abscess-causing Klebsiella pneumoniae CI, University of Queensland Early Career Research Project Grant 2018-2019, $35,000
  • Airborne transmission of microorganisms among persons with cystic fibrosis CI, Queensland Institute of Medical Research 2015-2018, $33,000
  • Transcriptome characterisation of Klebsiella pneumoniae during infection (TRACKIN) CI, NMHRC Early Career Fellowship (APP1088448) 2016-2019, $348,252
  • Transcriptome characterisation of Klebsiella pneumoniae during infection (TRACKIN) CI, European Respiratory Society/Marie Sklodowska-Curie RESPIRE2 Postdoctoral Research Fellowship 2014-2016, $93,104
  • Strategies to limit Psuedomonas aeruginosa acquisition and antimicrobial resistance in patients with CF CI, TPCH Foundation Project Grant 2016-2017, $98,000
  • Aerosols in chronic lung infection: their extent and how to prevent? CI, TPCH Foundation Project Grant 2014-2015, $99,576
  • Airborne transmission of microorganisms among persons with cystic fibrosis CI, Cystic Fibrosis Foundation Therapeutics Inc. Clinical Research Aware (USA) 2014-2016, $244,208
  • Clinical exploitation of genomics data produced by the Pseudomonas International Consortium Collaborator, CF Canada Project Grant 2013-2016, $665,000
  • Intra-strain diversity of Pseudomonas aeruginosa in the lungs of patients with CF and their role in exacerbation CI, TPCH Project Grant 2014-2016, $104,276
  • Intra-strain diversity of Pseudomonas aeruginosa in the lungs of patients with CF CI, TPCH Project Grant 2013-2014, $94,797
  • Biofilm behavior and hypermutation in P. aeruginosa infections in patients with CF CI, TPCH Foundation Project Grant 2012-2013, $83,610
  • Development of a novel assay for the detection of clonal P. aeruginosa in persons with CF CI, Australian CF Research Trust Project Grant 2011-2012, $68,950
  • Multilocus sequence typing of P. aeruginosa from different niches CI, Australian CF Research Trust Project Grant 2009-2010, $83,840
  • An epidemiological analysis of Burkholderia cepacia complex isolates from patients with cystic fibrosis CI, TPCH Foundation Project Grant 2002-2003, $30,000.

Memberships / Affiliations

Dr Timothy Kidd
Senior Scientist, Bacteriology
Pathology Queensland
email: timothy.kidd@health.qld.gov.au